文献速递炎症性肠病

显微性结肠炎与炎症性肠病发病风险:瑞典全国性队列研究

Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study.
PubMed 文献 · Gastroenterology · 2020-01-08

基于瑞典全国性前瞻性队列(显微性结肠炎13957例,匹配一般人群对照66820例及未受累同胞13943例),显微性结肠炎患者发生炎症性肠病(IBD)的风险显著升高,溃疡性结肠炎(UC)和克罗恩病(CD)的调整风险比分别为17.3和12.6,10年绝对超额风险分别为2.6和0.9个百分点。

要点

  • 显微性结肠炎患者发生IBD的风险显著增加,UC的aHR为17.3,CD的aHR为12.6。
  • 与未受累同胞比较,UC和CD的aHR分别为9.4和5.4,提示家族易感性不能完全解释该关联。
  • 10年绝对超额风险:UC为2.6个百分点,CD为0.9个百分点。

核心结论

  • 在瑞典全国性队列中,显微性结肠炎患者发生IBD的风险显著升高,UC和CD的调整风险比分别为17.3和12.6。

研究设计与样本

  • 前瞻性队列研究,纳入1990年至2017年瑞典全国28个中心经病理确诊的显微性结肠炎成人患者13957例,匹配一般人群对照66820例及未受累同胞13943例,采用Cox回归估计调整风险比。

主要发现

  • 显微性结肠炎患者中发生UC 323例、CD 108例,一般人群对照中发生UC 94例、CD 42例。
  • 从显微性结肠炎诊断到CD诊断的平均时间为3.3±3.2年,到UC诊断的平均时间为3.2±3.5年。
  • 多变量模型中,显微性结肠炎与CD的aHR为12.6(95%CI 8.8-18.1),与UC的aHR为17.3(95%CI 13.7-21.8),与IBD的aHR为16.8(95%CI 13.9-20.3)。
  • CD和UC的10年绝对超额风险分别为0.9(95%CI 0.7-1.1)和2.6(95%CI 2.2-2.9)个百分点。
  • 与未受累同胞比较,CD和UC的aHR分别为5.4(95%CI 3.2-9.2)和9.4(95%CI 6.4-13.8)。

临床怎么用

  • 对显微性结肠炎患者应关注IBD的发生风险,尤其在诊断后数年内。
  • 显微性结肠炎患者出现新发肠道症状时,需考虑IBD可能并进行相应评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Microscopic colitis shares pathogenetic mechanisms with inflammatory bowel disease (IBD). We studied the association between microscopic colitis and risk of incident IBD using data from a nationwide cohort study. METHODS: We conducted a prospective cohort study of all adults who received a diagnosis of microscopic colitis from 1990 through 2017 in Sweden and risk of incident IBD. Cases of microscopic colitis (n= 13,957) were identified through Systematized Nomenclature of Medicine codes from the ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden) study, which included gastrointestinal pathology reports from all of Sweden's 28 centers. Individuals with microscopic colitis were matched to 5 general population controls (n = 66,820) and to unaffected siblings (n =13,943). Cox regression was used to estimate adjusted hazard ratio (aHRs) and 95% confidence intervals (CIs). RESULTS: Through December of 2017, we identified 323 incident cases of ulcerative colitis (UC) and 108 incident cases of Crohn's disease (CD) in patients with microscopic colitis compared with 94 UC and 42 CD cases in population comparators. Mean times from diagnosis of microscopic colitis to diagnosis of CD was 3.3 ± 3.2 years and to diagnosis of UC was 3.2 ± 3.5 years. In multivariable models, microscopic colitis was associated with an aHR of 12.6 (95% CI 8.8-18.1) for CD, 17.3 (95% CI 13.7-21.8) for UC, and 16.8 (95% CI 13.9-20.3) for IBD. The 10-year absolute excess risks of CD and UC were 0.9 (95% CI 0.7-1.1) and 2.6 (95% CI 2.2-2.9) percentage points, respectively. In sensitivity analyses, comparing patients with microscopic colitis with their unaffected siblings, the aHRs of CD and UC were 5.4 (95% CI 3.2-9.2) and 9.4 (95% CI 6.4-13.8), respectively. CONCLUSIONS: In a population-based study in Sweden, we found a significant increase in risk of incident IBD among patients with microscopic colitis. Future studies should focus on potential mechanisms underlying these observed associations.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Khalili H, Burke KE, Roelstraete B, et al. Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study. Gastroenterology. 2020. PMID: 31926169. doi:10.1053/j.gastro.2019.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。